Join the A-Team in Boston for the CTAD Conference!
Meet Allucent’s neuroscience experts at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, where researchers, clinical development experts, and industry leaders come together to discuss advancements in Alzheimer’s disease research. Allucent’s Roberta Anderson, ACE Therapeutic Strategy Head, Neuroscience, will be at the conference to connect with fellow experts, discuss the evolving Alzheimer’s clinical development landscape, and share perspectives on advancing neuroscience programs.
Schedule a meeting with Roberta at CTAD 2026 to discuss your clinical development program or learn more about Allucent’s neuroscience expertise.
Fill out the form to schedule a meeting.
Attendees
Roberta Anderson, PhD, ACE Therapeutic Strategy Head, Neuroscience, Allucent
Roberta Anderson, PhD, is the ACE Therapeutic Strategy Head, Neuroscience at Allucent and brings nearly 30 years of clinical development experience with deep specialization in neuroscience. She has a broad range of indications experience across neurological disorders, including Alzheimer’s disease, stroke, sleep disorders, and Tourette’s Syndrome. She also has strong regulatory expertise guiding complex submissions and approvals (FDA INDs, Health Canada CTAs, SPA), with experience across multiple phases of development.
Share This
